Company Description

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.

It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels.

The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Evolus, Inc.

Country	United States
Founded	2012
IPO Date	Feb 8, 2018
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	332
CEO	David Moatazedi

Contact Details

Address: 520 Newport Center Drive, Suite 1200 Newport Beach, California 92660 United States
Phone	949 284 4555
Website	evolus.com

Stock Details

Ticker Symbol	EOLS
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001570562
CUSIP Number	30052C107
ISIN Number	US30052C1071
Employer ID	46-1385614
SIC Code	2834

Key Executives

Name	Position
David Moatazedi	President, Chief Executive Officer and Director
Sandra Beaver	Chief Financial Officer
Dr. Rui Avelar C.CFP, Dip.SportMed, M.D.	Chief Medical Officer and Head of Research and Development
Nareg Sagherian	Head of Global Investor Relations and Corporate Communications
Jeffrey J. Plumer	General Counsel
Kurt Knab	Senior Vice President of Sales
Tomoko Yamagishi-Dressler	Chief Marketing Officer
Jessica Novak	Senior Vice President of Human Resources

Latest SEC Filings

Date	Type	Title
Mar 12, 2025	144	Filing
Mar 4, 2025	S-8	Securities to be offered to employees in employee benefit plans
Mar 4, 2025	10-K	Annual Report
Mar 4, 2025	8-K	Current Report
Feb 6, 2025	SCHEDULE 13G/A	Filing
Feb 5, 2025	SCHEDULE 13G/A	Filing
Jan 21, 2025	8-K	Current Report
Dec 18, 2024	UPLOAD	Filing
Nov 14, 2024	SCHEDULE 13G/A	Filing
Nov 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals

View All SEC Filings